norepinephrine bitartrate · Baxter Hlthcare Corp · NDA 214313
Norepinephrine Bitartrate In 5% Dextrose
Earliest generic entry, as listed · earliest of 3 marketed strengths
8 Mar 2041
Blocked by patent: US 12097170, US 12290494, US 12714681.
Listed patents · 3 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12097170 | drug product, use U-3995 · sets the listed date | 8 Mar 2041 |
| US 12290494 | drug product · sets the listed date | 8 Mar 2041 |
| US 12714681 | drug product · sets the listed date | 8 Mar 2041 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 214313 · 001 · RLD | solution, intravenous | EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) | 8 Mar 2041 |
| 214313 · 002 · RLD | solution, intravenous | EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) | 8 Mar 2041 |
| 214313 · 003 · RLD | solution, intravenous | EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) | 8 Mar 2041 |